Combined Cosmetic or Therapeutic Preparation

• US 20070259050A1
• Filed: 11/04/2004
• Published: 11/08/2007
• Est. Priority Date: 11/11/2003
• Status: Abandoned Application

• Current Assignee: ROVI Cosmetics International GmbH (Rag-Stiftung)
• Original Assignee: ROVI GmbH & Company Kosmetishe Rotstoffe KG (Rag-Stiftung)
• Inventors: Teichmuller, Dirk, Blume, Gabriele
• Application Number:
  US10/579,121
• Publication Number:
  US 20070259050A1
• Time in Patent Office: Days
• US Class Current: 424/537
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/52 Purines, e.g. adenine
• CPC Class Codes: A61K 36/77 Sapindaceae (Soapberry family), e.g. lychee or soapberry
• CPC Class Codes: A61K 38/58 from leeches, e.g. hirudin, eglin
• CPC Class Codes: A61K 8/14 Liposomes; Vesicles
• CPC Class Codes: A61K 8/42 Amides
• CPC Class Codes: A61K 8/602 Glycosides, e.g. rutin
• CPC Class Codes: A61K 8/675 Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde tocopheryl nicotinate A61K8/678
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 9/14 Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
• CPC Class Codes: A61Q 19/00 Preparations for care of the skin

Abstract

A combined cosmetic or therapeutic preparation having a carrier system comprising membrane-forming lipids and at least two active ingredients which are selected from at least two of the groups (a) anti-coagulants, (b) vasoprotective agents and (c) microcirculation-promoting substances. The invention also includes the method for making the preparation from its ingredients.

Claims

1. A combined cosmetic or therapeutic preparation having a carrier system comprising membrane-forming lipids and at least two active ingredients which are selected from at least two of the groups

(a) anti-coagulants,

(b) vasoprotective agents and

(c) microcirculation-promoting substances.

2. A combined preparation according to claim 1 wherein the active ingredients are selected from the groups anti-coagulants (a) and vasoprotective agents (b).

3. A combined preparation according to claim 1 wherein the active ingredients are selected from the groups anti-coagulants (a) and microcirculation-promoting substances (c).

4. A combined preparation according to claim 1 wherein the active ingredients are selected from the groups vasoprotective agents (b) and microcirculation-promoting substances (c).

5. A combined preparation according to claim 1 wherein the active ingredients are selected from the groups anti-coagulants (a), vasoprotective agents (b) and microcirculation-promoting substances (c).

6. A combined preparation according to claim 1 wherein the carrier system is vesicular.

7. A combined preparation according to claim 1 wherein the membrane-forming lipids include the groups of phospholipids, ceramides and diacylglycosides.

8. A combined preparation according to claim 1 wherein the membrane-forming lipids contain at least 70% by weight of phosphatidylcholine, preferably about 80-90% by weight of phosphatidylcholine.

9. A combined preparation according to claim 1 wherein the anti-coagulants are selected from heparins, fucoidans, hirudins, pentapeptides, coumarin derivatives and mixtures thereof.

10. A combined preparation according to claim 1 wherein as the anti-coagulant it contains fucoidan, preferably low-molecular fucoidan, particularly preferably in an amount of 0.1-10% by weight.

11. A combined preparation according to claim 1 wherein the vasoprotective agents are selected from aescin, rutin, diosmin, ruscogenin and mixtures thereof.

12. A combined preparation according to claim 1 wherein it contains aescin as the vasoprotective agent, preferably in an amount of 0.1-7% by weight.

13. A combined preparation according to claim 1 wherein the microcirculation-promoting substances are selected from caffeine, naftidrofuryl, pentoxyfyllin, buflomedil and ginkgo active ingredients and mixtures thereof.

14. A combined preparation according to claim 1 wherein it contains caffeine as the microcirculation-promoting substance, preferably in an amount of 0.1-2% by weight.

15. A combined preparation according to claim 1 wherein it contains aescin, preferably in an amount of 4.0 to 6.0% by weight, particularly preferably 5.0% by weight, low-molecular fucoidan, preferably in an amount of 1.0 to 3.0% by weight, particularly preferably 2.0% by weight, and caffeine, preferably in an amount of 0.5 to 1.5% by weight, particularly preferably 1.0% by weight.

16. A combined preparation according to claim 1 wherein the carrier system additionally contains linoleic acid in stabilised form, preferably in an amount of 2.5 to 4.5% by weight.

17. A combined preparation according to claim 1 wherein it further contains at least one thermoreceptor-agonist which is selected from the group which includes natural or synthetic capsaicin, preferably in an amount of 0.1 to 1% by weight, particularly preferably in an amount of 0.2 to 0.6% by weight, and nicotinic acid, nicotinic acid amide, nicotinic acid ester or mixtures thereof, preferably in an amount of 0.5 to 5% by weight, particularly preferably in an amount of 0.5 to 3% by weight.

18. A combined preparation according to claim 1 wherein it further contains 10-25% by weight of ethanol.

19. A method for the production of a preparation for prophylaxis and/or treatment of hematomas comprising combining membrane-forming lipids and at least two active substances which are selected from at least two of the groups (a) anti-coagulants, (b) vasoprotective agents and (c) microcirculation-promoting substances.

20. The method of claim 19 wherein the preparation is for phophylaxis or treatment of hematomas of the lower eyelid, and/or veins.